Akebia Therapeutics

$3.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.29%) Today
+$0.02 (+0.58%) As of 10:39 AM UTC after-hours

Why Robinhood?

You can buy or sell AKBA and other stocks, options, and ETFs commission-free!

About AKBA

Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. The listed name for AKBA is Akebia Therapeutics, Inc. Common Stock.

CEO
John P. Butler
Employees
360
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
595.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
8.18M
High Today
$3.53
Low Today
$3.25
Open Price
$3.43
Volume
7.35M
52 Week High
$13.71
52 Week Low
$2.09

AKBA Earnings

-$0.79
-$0.58
-$0.38
-$0.17
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.40 per share
Actual
-$0.60 per share
Replay Earnings Call

You May Also Like

SINO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure